Liver X receptor agonist prevents the evolution of collagen-induced arthritis in mice.

Min Chan Park, Yong Jin Kwon, Soo Jin Chung, YongBeom Park, Soo Kon Lee

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Liver X receptors (LXRs) have been characterized as regulators of macrophage inflammatory pathways. Synthetic LXR agonists inhibit the macrophage response to bacterial pathogens and antagonize the induction of a number of pro-inflammatory genes. The aim of this study was to investigate the preventive effects of synthetic LXR agonist, GW3965, treatment on the evolution of arthritis and inflammatory response in a murine CIA model. Intradermal injection of bovine type II CIA in DBA/1 mice. Along with the induction of CIA, mice were treated with oral GW3965 (0.1, 0.3 or 1.0 mg/kg/day) or vehicle from Day 1 to Day 40. Clinical assessment for arthritis scores and histopathological assessment of joint sections were performed. The expression of inflammatory mediators was evaluated by immunohistochemical staining. Serum pro-inflammatory cytokine levels were determined using ELISA. The CIA incidence was 100% on Day 27 and the severity progressed until Day 35 with histological features of cartilage erosion in vehicle-treated mice. GW3965 treatment significantly reduced the arthritis incidence and attenuated the clinical and histological severity, compared with vehicle-treated mice. GW3965 treatment also significantly reduced inflammatory mediator production in joint sections and serum pro-inflammatory cytokine levels in a dose-dependent manner. These results indicate that activation of LXRs suppresses the onset of CIA and reduces inflammation and joint destruction in CIA mice. The data could suggest that LXR treatment is an effective prophylactic approach to suppress the evolution of synovitis and resultant joint destruction observed in RA.

Original languageEnglish
Pages (from-to)882-890
Number of pages9
JournalRheumatology (Oxford, England)
Volume49
Issue number5
DOIs
Publication statusPublished - 2010 Jan 1

Fingerprint

Experimental Arthritis
Joints
Arthritis
Macrophages
Cytokines
Intradermal Injections
Inbred DBA Mouse
Synovitis
Incidence
Therapeutics
Serum
Cartilage
Enzyme-Linked Immunosorbent Assay
Liver X Receptors
Staining and Labeling
Inflammation
GW 3965
Genes

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Pharmacology (medical)

Cite this

Park, Min Chan ; Kwon, Yong Jin ; Chung, Soo Jin ; Park, YongBeom ; Lee, Soo Kon. / Liver X receptor agonist prevents the evolution of collagen-induced arthritis in mice. In: Rheumatology (Oxford, England). 2010 ; Vol. 49, No. 5. pp. 882-890.
@article{ae1f07b0e1d548ceb1c769d22feef427,
title = "Liver X receptor agonist prevents the evolution of collagen-induced arthritis in mice.",
abstract = "Liver X receptors (LXRs) have been characterized as regulators of macrophage inflammatory pathways. Synthetic LXR agonists inhibit the macrophage response to bacterial pathogens and antagonize the induction of a number of pro-inflammatory genes. The aim of this study was to investigate the preventive effects of synthetic LXR agonist, GW3965, treatment on the evolution of arthritis and inflammatory response in a murine CIA model. Intradermal injection of bovine type II CIA in DBA/1 mice. Along with the induction of CIA, mice were treated with oral GW3965 (0.1, 0.3 or 1.0 mg/kg/day) or vehicle from Day 1 to Day 40. Clinical assessment for arthritis scores and histopathological assessment of joint sections were performed. The expression of inflammatory mediators was evaluated by immunohistochemical staining. Serum pro-inflammatory cytokine levels were determined using ELISA. The CIA incidence was 100{\%} on Day 27 and the severity progressed until Day 35 with histological features of cartilage erosion in vehicle-treated mice. GW3965 treatment significantly reduced the arthritis incidence and attenuated the clinical and histological severity, compared with vehicle-treated mice. GW3965 treatment also significantly reduced inflammatory mediator production in joint sections and serum pro-inflammatory cytokine levels in a dose-dependent manner. These results indicate that activation of LXRs suppresses the onset of CIA and reduces inflammation and joint destruction in CIA mice. The data could suggest that LXR treatment is an effective prophylactic approach to suppress the evolution of synovitis and resultant joint destruction observed in RA.",
author = "Park, {Min Chan} and Kwon, {Yong Jin} and Chung, {Soo Jin} and YongBeom Park and Lee, {Soo Kon}",
year = "2010",
month = "1",
day = "1",
doi = "10.1093/rheumatology/keq007",
language = "English",
volume = "49",
pages = "882--890",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "5",

}

Liver X receptor agonist prevents the evolution of collagen-induced arthritis in mice. / Park, Min Chan; Kwon, Yong Jin; Chung, Soo Jin; Park, YongBeom; Lee, Soo Kon.

In: Rheumatology (Oxford, England), Vol. 49, No. 5, 01.01.2010, p. 882-890.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Liver X receptor agonist prevents the evolution of collagen-induced arthritis in mice.

AU - Park, Min Chan

AU - Kwon, Yong Jin

AU - Chung, Soo Jin

AU - Park, YongBeom

AU - Lee, Soo Kon

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Liver X receptors (LXRs) have been characterized as regulators of macrophage inflammatory pathways. Synthetic LXR agonists inhibit the macrophage response to bacterial pathogens and antagonize the induction of a number of pro-inflammatory genes. The aim of this study was to investigate the preventive effects of synthetic LXR agonist, GW3965, treatment on the evolution of arthritis and inflammatory response in a murine CIA model. Intradermal injection of bovine type II CIA in DBA/1 mice. Along with the induction of CIA, mice were treated with oral GW3965 (0.1, 0.3 or 1.0 mg/kg/day) or vehicle from Day 1 to Day 40. Clinical assessment for arthritis scores and histopathological assessment of joint sections were performed. The expression of inflammatory mediators was evaluated by immunohistochemical staining. Serum pro-inflammatory cytokine levels were determined using ELISA. The CIA incidence was 100% on Day 27 and the severity progressed until Day 35 with histological features of cartilage erosion in vehicle-treated mice. GW3965 treatment significantly reduced the arthritis incidence and attenuated the clinical and histological severity, compared with vehicle-treated mice. GW3965 treatment also significantly reduced inflammatory mediator production in joint sections and serum pro-inflammatory cytokine levels in a dose-dependent manner. These results indicate that activation of LXRs suppresses the onset of CIA and reduces inflammation and joint destruction in CIA mice. The data could suggest that LXR treatment is an effective prophylactic approach to suppress the evolution of synovitis and resultant joint destruction observed in RA.

AB - Liver X receptors (LXRs) have been characterized as regulators of macrophage inflammatory pathways. Synthetic LXR agonists inhibit the macrophage response to bacterial pathogens and antagonize the induction of a number of pro-inflammatory genes. The aim of this study was to investigate the preventive effects of synthetic LXR agonist, GW3965, treatment on the evolution of arthritis and inflammatory response in a murine CIA model. Intradermal injection of bovine type II CIA in DBA/1 mice. Along with the induction of CIA, mice were treated with oral GW3965 (0.1, 0.3 or 1.0 mg/kg/day) or vehicle from Day 1 to Day 40. Clinical assessment for arthritis scores and histopathological assessment of joint sections were performed. The expression of inflammatory mediators was evaluated by immunohistochemical staining. Serum pro-inflammatory cytokine levels were determined using ELISA. The CIA incidence was 100% on Day 27 and the severity progressed until Day 35 with histological features of cartilage erosion in vehicle-treated mice. GW3965 treatment significantly reduced the arthritis incidence and attenuated the clinical and histological severity, compared with vehicle-treated mice. GW3965 treatment also significantly reduced inflammatory mediator production in joint sections and serum pro-inflammatory cytokine levels in a dose-dependent manner. These results indicate that activation of LXRs suppresses the onset of CIA and reduces inflammation and joint destruction in CIA mice. The data could suggest that LXR treatment is an effective prophylactic approach to suppress the evolution of synovitis and resultant joint destruction observed in RA.

UR - http://www.scopus.com/inward/record.url?scp=79952481326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952481326&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keq007

DO - 10.1093/rheumatology/keq007

M3 - Article

VL - 49

SP - 882

EP - 890

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 5

ER -